Our Mission
Our mission is to significantly accelerate innovation cycles in biopharmaceutical industry by combining proprietary scaling lab technology using protein crystals and machine learning.
Our Technology
CrystalsFirst proprietary technology realizes the potential of 3D-models for structure-guided drug design and meets the high demand for bio-structural data to
-
tailor the compounds for high affinity, selectivity, safety, and efficacy,
-
identify new modes of action for drug candidates,
-
enter design paths of allosteric modulators,
-
tap into unexplored IP and chemical spaces,
-
and increase efficiency of the drug pipeline.
The core technology SmartSoak® is integrated into an in-house modular ecosystem, which provides more specifically
- hit identification and optimization in challenging projects,
- faster cycle times from ligand to 3D structure,
- higher throughput of 3D-models for structural insight,
- flexible application of compound libraries in crystallographic screening.
OUR SCIENTIFIC APPROACH AND STRATEGIC VISION
CrystalsFirst is committed to the constant improvement and expansion of its technology platform to better unlock the strategic advantages of structure- and fragment-based drug discovery.
Our technology renders complex trial & error approaches obsolete, ascertains the druggability of a given target, and ensures early and unambiguous identification of binders by crystallographic analysis.
Team
Dr. Serghei Glinca, MBA
Chief Executive Officer
Dr. Stefan Merkl
Chief Scientific Officer
Bernd Scheld
Chief Financial Officer
Christian Rötz
Chief Operations Officer
Dr. Janis Müller
Principal Scientist
Moritz Ruf
Principal Scientist
Anna Trodler
Research Intern
Scientific Advisory Board
Prof. Dr. Gerhard Klebe
Philipps University Marburg
Dr. Gerhard Müller
Gotham Therapeutics New York
Dr. Manfred S. Weiss
Helmholtz Zentrum Berlin
CrystalsFirst GmbH
Marbacher Weg 6 | 35037 Marburg
Germany
